| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,4 Md € | +44.5% | 3,8 Md € | -11.1% | 4,2 Md € | -35.2% | 6,5 Md € | +8.7% | 6,0 Md € | +42.3% | 4,2 Md € | +26.1% | 3,3 Md € | +3.1% | 3,2 Md € | +14.4% | 2,8 Md € | +23.2% | 2,3 Md € | -18.1% | 2,8 Md € | +0.7% | 2,8 Md € | -8.6% | 3,1 Md € | -31.1% | 4,4 Md € | +1.7% | 4,4 Md € | +74.5% | 2,5 Md € | +32.7% | 1,9 Md € | |
| EBITDA | 156,7 M € | +202.7% | -152,7 M € | -151.2% | 298,0 M € | +11.7% | 266,9 M € | -27.2% | 366,8 M € | +206.3% | 119,7 M € | +5.2% | 113,8 M € | -42.6% | 198,5 M € | +36.4% | 145,5 M € | +83.2% | 79,4 M € | -50.4% | 160,1 M € | +20.4% | 132,9 M € | -29.3% | 188,0 M € | -17.9% | 228,9 M € | +0.9% | 226,8 M € | +30.1% | 174,4 M € | +89.4% | 92,1 M € | |
| Operating profit | 53,3 M € | +118.0% | -295,8 M € | -323.6% | 132,3 M € | -17.6% | 160,5 M € | -42.9% | 281,4 M € | +1376.3% | -22,0 M € | -308.6% | -5,4 M € | -105.6% | 95,5 M € | +59.8% | 59,8 M € | +1868.7% | 3,0 M € | -95.8% | 72,5 M € | +7.0% | 67,8 M € | -38.4% | 109,9 M € | -31.1% | 159,6 M € | +0.4% | 158,9 M € | +26.5% | 125,6 M € | +169.4% | 46,6 M € | |
| Profit/loss | 104,4 M € | +146.8% | -222,8 M € | -183.0% | 268,4 M € | -9.5% | 296,7 M € | -4.2% | 309,7 M € | +258.2% | 86,5 M € | -58.7% | 209,3 M € | -7.8% | 227,0 M € | +51.5% | 149,8 M € | +0.9% | 148,5 M € | +9.7% | 135,5 M € | +3.2% | 131,2 M € | +49.2% | 88,0 M € | -40.0% | 146,7 M € | -6.0% | 156,2 M € | -48.6% | 303,7 M € | +50.7% | 201,6 M € | |
| Equity | 2,1 Md € | -0.8% | 2,1 Md € | -14.0% | 2,5 Md € | +3.0% | 2,4 Md € | +4.4% | 2,3 Md € | +5.5% | 2,2 Md € | -4.1% | 2,3 Md € | +5.6% | 2,1 Md € | +77.5% | 1,2 Md € | -0.9% | 1,2 Md € | +0.6% | 1,2 Md € | +0.2% | 1,2 Md € | -15.1% | 1,4 Md € | -1.6% | 1,4 Md € | +2.5% | 1,4 Md € | +3.3% | 1,4 Md € | +18.7% | 1,2 Md € | |
| Total assets | 6,3 Md € | -6.3% | 6,7 Md € | +7.3% | 6,2 Md € | +0.9% | 6,2 Md € | +13.0% | 5,5 Md € | +4.4% | 5,2 Md € | +12.9% | 4,6 Md € | +21.4% | 3,8 Md € | -24.7% | 5,1 Md € | +10.2% | 4,6 Md € | +1.8% | 4,5 Md € | -2.3% | 4,6 Md € | -2.0% | 4,7 Md € | -0.6% | 4,7 Md € | -6.5% | 5,1 Md € | +5.2% | 4,8 Md € | +12.3% | 4,3 Md € | |
| Cash | 8,9 M € | -84.1% | 55,8 M € | +597.1% | 8,0 M € | +74.1% | 4,6 M € | +723.2% | 559,1 k € | -87.8% | 4,6 M € | +108.4% | 2,2 M € | -44.4% | 3,9 M € | +405.0% | 779,7 k € | -59.0% | 1,9 M € | +99.8% | 951,2 k € | +33.6% | 711,9 k € | -37.1% | 1,1 M € | -16.1% | 1,3 M € | +147.2% | 545,5 k € | -86.6% | 4,1 M € | +90.3% | 2,1 M € | |
| Debts | 3,5 Md € | -15.5% | 4,1 Md € | +25.1% | 3,3 Md € | -5.1% | 3,4 Md € | +19.8% | 2,9 Md € | +3.9% | 2,8 Md € | +28.4% | 2,2 Md € | +48.7% | 1,5 Md € | -60.4% | 3,7 Md € | +15.5% | 3,2 Md € | +1.3% | 3,1 Md € | -3.1% | 3,2 Md € | +3.2% | 3,1 Md € | +0.2% | 3,1 Md € | -10.4% | 3,5 Md € | +5.9% | 3,3 Md € | +10.1% | 3,0 Md € | |
| Staff | 3 209 | 3 322,9 | 3 255,7 | 3 077,4 | 3 004,3 | 3 025,1 | 3 001,9 | 2 832,9 | 2 683,2 | 2 644,1 | 2 745,2 | 2 893,7 | 2 922,5 | 2 978,7 | 2 909,3 | 2 791,5 | 2 764,4 | |||||||||||||||||
Public limited company · Bruxelles · incorporated on 07/07/1904 · 3 209,0 ETP
Public limited company profitable and well capitalised. Cash position declining (-84.1%).
Solid counterparty for a standard engagement.
| Unit no. | Name | Location |
|---|---|---|
| 2105027979 | UMICORE | Rue du Marais 31, 1000 Bruxelles |
| 2105028474 | UMICORE | Adolf Greinerstraat 14, 2660 Antwerpen |
| 2105029959 | UMICORE | Watertorenstraat 33, 2250 Olen |
| 2380990902 | — | Rendelaar z/n, 2250 Olen |
| 2273298433 | Umicore | Industrieweg 34 box 3, 2280 Grobbendonk |
| 2319223676 | UMICORE | Watertorenstraat 37A, 2250 Olen |
UMICORE is a Public limited company incorporated in 1904. Its main activity is: Fabrication d’autres produits chimiques organiques de base. Its registered office is in Bruxelles. It employs on average 3 209,0 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette